Clinical Research Coordinators are the operational backbone of clinical trials — managing regulatory submissions, patient recruitment, protocol compliance, data integrity, and sponsor communications across studies that can span years. These 35 prompts help CRCs draft correspondence, prepare for audits, write SOPs, and communicate research concepts clearly to participants and colleagues.
Note: these prompts are designed to support — not replace — your professional judgment and institutional review processes. Always validate AI-generated content against your protocol, IRB requirements, and regulatory guidelines.
1. Informed Consent and Participant Communication
Help me rewrite the following informed consent section in plain language at a 6th-grade reading level. The original text is: [paste section]. Keep all required regulatory elements (purpose, procedures, risks, benefits, alternatives, confidentiality, voluntary participation) but replace technical jargon with everyday language. Aim for short sentences and active voice.
Write a participant recruitment script for a phone screening call for a Phase II clinical trial studying a new oral medication for moderate-to-severe rheumatoid arthritis. The call should: introduce the study, explain the commitment involved (12 visits over 18 months), screen for basic eligibility (age 18-70, RA diagnosis, on stable background therapy), and invite the participant to an in-person screening visit. Tone should be warm, informative, and never coercive.
Draft a participant newsletter update for an ongoing 3-year cardiovascular outcomes trial. This is month 18. Key updates: enrollment is complete (1,200 participants enrolled), the study is proceeding as planned, participants should continue their study medication and scheduled visits, and we are grateful for their continued participation. Make it personal, encouraging, and approximately 300 words. Avoid unblinding any information.
A study participant is considering withdrawing from the trial due to transportation difficulties getting to clinic visits. Write a compassionate script for a conversation addressing their concern, exploring solutions (transportation assistance, telehealth visits if allowed by protocol), and ensuring they understand their right to withdraw without penalty — while also conveying what their continued participation means to the research without being coercive.
Write a lay summary of a Phase III oncology trial for potential participants with no scientific background. The trial is testing a novel immunotherapy agent combined with standard chemotherapy in patients with newly diagnosed stage III non-small cell lung cancer. Explain: what the study is testing, why it matters, what participation involves, and what the potential risks and benefits are. Maximum 400 words.
2. Regulatory and IRB Documentation
Help me draft a protocol deviation report for submission to the IRB. The deviation: a participant completed their Month 6 visit 14 days outside the allowed visit window (window: ±7 days) due to a family emergency. The visit procedures were completed in full and no safety concerns were noted. Include: description of the deviation, root cause, immediate corrective actions taken, and steps to prevent recurrence.
Write a continuing review (CR) application narrative for an IRB annual renewal. The study is a Phase II, randomized, double-blind trial of a topical wound-healing agent in diabetic foot ulcers. Current enrollment: 68/100 participants. Two serious adverse events (both unrelated to study drug per investigator assessment). No protocol deviations in the past year. Study completion projected in 12 months. Summarize study status and justify continued approval.
Draft an IRB amendment cover letter requesting approval for a protocol amendment. We need to: add a new blood draw at the Month 3 visit (15 mL additional), add a site in Houston, TX, and revise the inclusion criteria to allow participants up to age 75 (currently capped at 70). Explain the rationale for each change and note that a revised consent form is included.
Help me write the regulatory submission cover letter to the FDA for an IND Safety Report. The event is a serious unexpected suspected adverse reaction (SUSAR): one participant in our Phase I oncology study experienced Grade 4 hepatotoxicity (elevated LFTs > 10x ULN) occurring on Day 14 of dosing. Include the required elements per 21 CFR 312.32. Flag this as an expedited 7-day report.
Write a response to an IRB request for clarification. The IRB asked: "Please clarify how participant confidentiality will be protected given that the study involves video-recorded behavioral assessments." Explain our data security plan: videos stored on encrypted institutional servers, access restricted to study team members with completed HIPAA training, videos de-identified after analysis, and no videos shared with the sponsor.
3. Protocol Compliance and Visit Management
Create a study visit checklist for a Phase III hypertension trial Month 12 assessment visit. The visit includes: vital signs, 12-lead ECG, fasting labs (CBC, CMP, lipid panel, HbA1c), pill count for study medication, concomitant medication review, adverse event assessment, completion of 3 patient-reported outcome instruments (SF-36, PGIC, PHQ-9), and dispensing of next month's study medication. Format as a step-by-step checklist with space for initials and timestamps.
Help me write a participant visit reminder script for a 48-hour phone call prior to a fasting blood draw visit. Include: fasting instructions (nothing by mouth after midnight except water and approved medications), what to bring (insurance card, photo ID, list of current medications), what to expect at the visit (arrival time, duration approximately 2 hours), parking instructions, and a contact number for questions. Tone: friendly and organized.
A participant has reported a new medication they started taking (a statin) since their last study visit. Help me create a decision-making framework for assessing concomitant medication changes in a clinical trial. What are the key questions to answer, how do I check the protocol's prohibited medications list, who to notify and when, and how to document the finding?
Write a source document template for an adverse event (AE) report. Include fields for: AE description (verbatim and coded term), start and end date, severity grade (CTCAE), relationship to study drug (5 categories), action taken, outcome, and whether criteria for a serious AE (SAE) were met. Include a free-text narrative field for clinical context.
Help me draft a protocol for managing a missed visit. A participant missed their Month 3 visit (window expired yesterday). Outline the steps: contact attempts, documentation requirements, what procedures can still be completed (and within what timeframe), when the investigator must be notified, whether a protocol deviation report is required, and how to update the subject status in the EDC.
4. Data Management and Quality Control
Help me create a data entry quality control checklist for our EDC (electronic data capture) system. Include checks for: completeness (all required fields entered), accuracy (values within plausible physiological ranges), consistency (dates are sequential, AE onset after first dose), and audit trail integrity. Format as a weekly QC process a CRC can complete in 30 minutes.
Write a data discrepancy query response for the following sponsor query: "CRF Page 4, Visit 2: The recorded systolic blood pressure (188 mmHg) appears inconsistent with the source document notation of 138 mmHg. Please clarify and correct if needed." Draft a response that: acknowledges the query, explains the source (a transcription error), confirms the correct value from source documents, and describes the correction process per GCP guidelines.
Help me write a missing data management plan for our trial. We expect approximately 8% missing data in our primary endpoint (MMSE score at Month 12) due to early withdrawal. Cover: categories of missing data (MCAR, MAR, MNAR), our planned statistical approach for handling each (LOCF, multiple imputation, mixed model repeated measures), how this will be pre-specified in the SAP, and sensitivity analyses planned.
I need to prepare a CRF completion guidelines document for investigative site staff. Cover: general principles (contemporaneous documentation, legibility, no white-out), how to make corrections (single line strikethrough, date, initial), handling of unknown vs. not done vs. not applicable, and 5 common errors seen in EDC data with specific guidance on how to avoid each.
Write a site initiation visit (SIV) training agenda for a new investigative site being activated on a Phase III cardiovascular outcomes trial. Include sessions on: protocol overview and rationale, eligibility criteria and screening process, study procedures and visit schedule, informed consent process, adverse event reporting, EDC training, pharmacy and drug accountability, and regulatory documentation requirements. Allow 6 hours total.
5. Sponsor and Monitor Communications
Draft a pre-monitoring visit communication email to a CRA (Clinical Research Associate) from the sponsor. The monitoring visit is scheduled for next Tuesday. Include: a visit confirmation, list of documents that will be available (regulatory binder, source documents, drug accountability logs, subject files), expected visit logistics (room reserved, PI availability for 1 hour at 10am), and a request for the visit agenda in advance.
Help me write a response to a sponsor finding from a monitoring visit report. The finding states: "At 3 of 12 source document reviews, the investigator's signature on the informed consent form was not documented within 24 hours of the participant signing." Draft a CAPA (Corrective Action and Preventive Action) response including: description of the issue, root cause analysis, immediate corrective actions, preventive actions for future subjects, and evidence of implementation.
Write a site feasibility questionnaire response for a new Phase II oncology trial. Our site has: a dedicated GI oncology clinic, 2 qualified investigators, a CRC with 6 years of experience, a Phase I unit with infusion chairs, access to a CLIA-certified laboratory, and a potential pool of 40 eligible patients per year based on our tumor registry. Format the response to highlight our site's strengths and address any potential challenges honestly.
Draft a letter to the sponsor requesting a protocol deviation waiver for a participant who was enrolled 2 days before they turned 18 (the minimum age per protocol is 18). The participant is now 18, consented appropriately, completed the baseline visit, and has had no safety issues. Present the case for allowing the participant to continue on study.
Help me write the site section of a clinical study report (CSR) contribution. Our site enrolled 28 participants, 26 completed the study (2 withdrew, 1 lost to follow-up, 1 withdrew consent). We had 1 SAE (unrelated), 0 protocol deviations, and no major compliance findings at monitoring visits. Format per ICH E3 guidelines.
6. SOP Writing and Training
Write a standard operating procedure (SOP) for the informed consent process at a clinical research site. Include: purpose and scope, responsibilities (PI, CRC, sub-investigator), step-by-step procedure (pre-consent preparation, consent discussion, documentation, re-consent triggers), references (21 CFR 50, ICH GCP E6(R2)), and a documentation checklist. Format per GCP SOP standards.
Draft an SOP for adverse event identification, grading, and reporting in clinical trials at our investigative site. Cover: definitions (AE, SAE, SUSAR, AESI), CTCAE grading, assessment of relationship to study drug, timeframes for internal escalation and sponsor/IRB reporting, documentation requirements in source and CRF, and follow-up until resolution.
Create a training assessment quiz for new CRC staff on GCP fundamentals. Write 10 multiple-choice questions covering: informed consent requirements, source document standards, protocol deviation vs. violation, SAE reporting timelines, investigator responsibilities, and data integrity principles. Include the correct answer and a brief explanation for each question.
Help me write an SOP for drug accountability and investigational product management at a clinical trial site. Cover: receipt and storage requirements (temperature monitoring, access controls), dispensing procedures, return and destruction processes, drug accountability log requirements, what to do in case of a temperature excursion, and reconciliation at study close-out.
Write a delegation of authority log template and a companion SOP section explaining how to complete it. The delegation log should capture: task name, the GCP/regulatory basis for delegation, whether training is required, the delegated team member's name, credentials, training completion date, and investigator signature of delegation. Include guidance on what tasks can and cannot be delegated.
7. Study Close-Out and Reporting
Help me write a study close-out visit preparation checklist for a Phase III trial wrapping up at our site. Include: regulatory document reconciliation, CRF completion verification, outstanding query resolution, investigational product return/destruction documentation, lab kit returns, equipment calibration records, archiving requirements (paper and electronic), and final financial reconciliation. Target timeline: 4 weeks before the close-out visit.
Draft a final narrative for the site's contribution to an annual progress report to the IRB for a study that has completed enrollment but is still in the follow-up phase. Enrollment: 45/45 participants. Current status: 38 participants actively in follow-up, 5 completed, 2 withdrew. AEs: 4 related AEs (all Grade 1-2, resolved), 1 unrelated SAE (hospitalization, resolved). No protocol deviations. Request 12-month continuation.
Write a lessons-learned document for our research team after the close-out of a 4-year multi-site trial. Our site enrolled 89 participants, exceeded our target of 80. Key challenges: recruitment slowdowns in Year 2, EDC system change mid-study, high CRC turnover. Key successes: strong participant retention (94%), zero critical findings at monitoring visits, excellent PI engagement. Format as a practical document future CRCs can learn from.
Help me write a cover letter for our regulatory binder at study close-out, confirming that all required essential documents have been archived. The letter should confirm: ICH GCP E6(R2) essential documents are complete, archiving medium (electronic and paper), storage location, retention period (15 years per FDA), and site contact for future access requests.
Draft a thank-you letter to participants at study close-out for a 3-year diabetes prevention trial. Express genuine appreciation for their time and commitment, share a brief lay summary of what the study data contributed (without revealing blinded results), let them know when results are expected to be published and how they can access them, and wish them well in their ongoing health journey.
Get the Complete Clinical Research Coordinator AI Toolkit
Get the complete AI Prompt Toolkit for Clinical Research Coordinators →
Works with Claude, ChatGPT, and DeepSeek. Copy-paste ready.
Top comments (0)